RIDDLE&CODE
31.5.2022 10:17:11 CEST | Business Wire | Press release
RIDDLE&CODE is now a member of the Catena-X Automotive Network e.V, an automotive association formed by leading industry players. Both Catena-X and RIDDLE&CODE aim to establish a decentralised data ecosystem through tokenization, tamper-proof identities, and digital twins of machines, vehicles and their components.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005104/en/
Catena-X is dedicated to developing an open, scalable industrial ecosystem that provides a data space and secure processes for all contributors across the automotive industry. The idea is to create a network where manufacturers, suppliers and all those involved in the value chain can participate in creating consistent means for data sharing and standardisation.
About the Catena-X Automotive Network
The Catena-X ecosystem consists of a consortium of 28 members from the automotive, business and scientific communities. It is funded by the German Ministry of Economic Affairs and Climate Action 0. The automotive industry launched a Public Association in 2021, which includes companies that actively want to shape the Catena-X ecosystem l. RIDDLE&CODE has become a member of the Association.
The strategic goal of Catena-X is to implement a standardised ecosystem across the automotive industry. This incentive was initiated by German companies in the automotive sector. It will then be adopted by the entirety of the European automobile industry and beyond.
While the Gaia-X infrastructure initiative aims to provide sovereign access to data via shared services for various industries, Catena-X specifically caters to the automotive industry. Data monetisation and implementation of token-based ecosystems are essential parts of the project. This has been done to drive these industry segments in the right direction of the environmental, social and governance (ESG) goals on different levels.
RIDDLE&CODE’s reasons to join
RIDDLE&CODE will contribute to the Catena-X network by bringing in its expertise in blockchain frameworks. This has been demonstrated through projects such as the European Blockchain Services Infrastructure PCP. RIDDLE&CODE, along with other partners, introduced a truly European architecture dubbed ZENBRIDGE. The project is supported by the European Commission.
Our ambition is to accelerate the move towards a transparent automotive ecosystem where data can be shared easily without facing obstacles from different proprietary infrastructures. Since its inception, RIDDLE&CODE has tackled these challenges.
"We are joining the association and partners to add our Trusted Car Wallet and Distributed Ledger Technology (DLT) software stack to the upcoming connected car data standards," said Minh Cao, Director of Mobility & Automotive at RIDDLE&CODE. "Our focus is to guarantee robust data directly from vehicles, providing trust and transparency to enable automation driven by AI and confidential edge computing."
"The objective is,” he continued, “to build a professional, standardised and modular toolchain for original equipment manufacturers (OEM) developers in the automotive ACES (Automated, Connected, Electric and Shared) and micromobility space that enables rapid prototyping of blockchain-based mobility solutions that leverage cryptographic techniques for data attestation and integration: tokenomics, decentralised data markets & data-rich vehicle networks. The RIDDLE&CODE toolchain will reduce complexity and simplify experimentation so that users can focus on building value-added business models whilst protecting manufacturers' intellectual property (IP)."
Catena-X includes major market shareholders such as BMW AG, Deutsche Telekom AG, Robert Bosch GmbH, Siemens AG, Mercedes-Benz AG and many more. Our membership will include exchanging ideas and technologies to further enrich this initiative.
About RIDDLE&CODE
RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About the Catena-X Automotive Network
Catena-X sees itself as a rapidly scalable, interoperable ecosystem in which all contributors in the automotive value chain can participate equally. The goal: to provide room for the creation, operation and collaborative use of end-to-end data chains along the entire automotive value chain. As of May 1st 2022, the Catena-X Automotive Network e.V. has 96 members who are active as providers and users in the automotive value chain and cover a wide range of company sizes.
More information: www.catena-x.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005104/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom